944 / 1266
A Phase 1 Study of AZD6244 in Children with Recurrent
or Refractory Low Grade Gliomas: A Pediatric Brain
Tumor Consortium Report
Responses
•8 subjects with radiographic partial response
•6 of 8 PRs observed in subjects treated at MTD (
25
mg/m2/dose)
•
Objective response rate at MTD = 6/24 (25%)
•5 of 8 subjects with PR had sufficient tissue for BRAF
studies; 4 of these 5 had a BRAF mutation (n=1) or fusion
(n=3)